Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients

American Journal of Hematology

Volumn 88, Issue 6, 2013, Pages 503-506

  Taher, Ali T ^a   Porter, John B ^b   Viprakasit, Vip ^c   Kattamis, Antonis ^d   Chuncharunee, Suporn ^e   Sutcharitchan, Pranee ^f   Siritanaratkul, Noppadol ^c   Galanello, Renzo ^g   Karakas, Zeynep ^h   Lawniczek, Tomasz ⁱ   Habr, Dany ⁱ   Ros, Jacqueline ⁱ   Zhang, Yiyun ⁱ   Cappellini, M Domenica ^j  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c MAHIDOL UNIVERSITY   (Thailand)

^d UNIVERSITY OF ATHENS   (Greece)

^e MAHIDOL UNIVERSITY   (Thailand)

^f CHULALONGKORN UNIVERSITY   (Thailand)

^g Evolutiva/Osp Reg Microcitemie ASL   (Italy)

^h ISTANBUL UNIVERSITY   (Turkey)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

^j UNIVERSITY OF MILAN   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; FERRITIN; IRON;

ALPHA THALASSEMIA; ARTICLE; BETA THALASSEMIA; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; IRON CHELATION; IRON OVERLOAD; LIVER LEVEL; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPLENECTOMY; UPPER ABDOMINAL PAIN;

ADULT; BENZOATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FERRITINS; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER; MALE; THALASSEMIA; TRIAZOLES; YOUNG ADULT;

EID: 84878169574     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23445     Document Type: Article

References (20)

1. Taher AT, Cappellini MD, Musallam KM. Recent advances and treatment challenges in patients with non-transfusion-dependent thalassemia: Introduction. Blood Rev 2012;26(Suppl 1):S1-S2.
2. Gardenghi S, Grady RW, Rivella S. Anemia, ineffective erythropoiesis, and hepcidin: Interacting factors in abnormal iron metabolism leading to iron overload in beta-thalassemia. Hematol Oncol Clin North Am 2010;24:1089-1107.
3. Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis 2010;5:11.
4. Harteveld CL, Higgs DR. Alpha-thalassaemia. Orphanet J Rare Dis 2010;5:13.
5. Muncie HL Jr, Campbell J. Alpha and beta thalassemia. Am Fam Physician 2009;80:339-344.
6. Taher AT, Musallam KM, Cappellini MD, Weatherall DJ. Optimal management of β-thalassaemia intermedia. Br J Haematol 2011;152:512-523.
7. Vichinsky E. Hemoglobin E syndromes. Hematology Am Soc Hematol Educ Program 2007;79-83.
8. Anuwatanakulchai M, Pootrakul P, Thuvasethakul P, Wasi P. Non-transferrin plasma iron in beta-thalassaemia/Hb E and haemoglobin H diseases. Scand J Haematol 1984;32:153-158.
9. Pootrakul P, Rugkiatsakul R, Wasi P. Increased transferrin iron saturation in splenectomized thalassaemic patients. Br J Haematol 1980;46:143-145.
10. Pootrakul P, Vongsmasa V, La-ongpanich P, Wasi P. Serum ferritin levels in thalassemias and the effect of splenectomy. Acta Haematol 1981;66:244-250.
11. Taher AT, Musallam KM, El-Beshlawy A, et al. Age-related complications in treatment-naive patients with thalassaemia intermedia. Br J Haematol 2010;150:486-489.
12. Cappellini MD, Fargion SR, Sampietro M, et al. Nontransfusional iron overload in thalassemia intermedia: Role of the hemochromatosis allele. Blood 1998;92:4479-4480.
13. Lok CY, Merryweather-Clarke AT, Viprakasit V, et al. Iron overload in the Asian community. Blood 2009;114:20-25.
14. Musallam KM, Cappellini MD, Wood JC, Taher AT. Iron overload in non-transfusion-dependent thalassemia: A clinical perspective. Blood Rev 2012;26(Suppl 1):S16-S19.
15. Olivieri NF, de Silva S, Premawardena A, et al. Iron overload and iron-chelating therapy in hemoglobin E-beta thalassemia. J Pediatr Hematol Oncol 2000;22:593-597.
16. Musallam KM, Cappellini MD, Wood JC, et al. Elevated liver iron concentration is a marker of increased morbidity in patients with β-thalassemia intermedia. Haematologica 2011;96:1605-1612.
17. Taher AT, Porter J, Viprakasit V, et al. Deferasirox significantly reduces iron overload in non-transfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood 2012;120:970-977.
18. St Pierre TG, Clark PR, Chua-anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005;105:855-861.
19. Taher A, Cappellini MD, Vichinsky E, et al. Efficacy and safety of deferasirox doses of >30mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol 2009;147:752-759.
20. Brewer C, Otto-Duessel M, Lykkesfeldt J, et al. Ascorbate status modulates reticuloendothelial iron stores and response to deferasirox iron chelation in ascorbate-deficient rats. Exp Hematol 2012;40:820-827.